ArticleiScience2026
Efficacy and safety of adding induction therapy for unresectable NSCLC receiving cCRT and consolidation immunotherapy: A retrospective study.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concurrent chemoradiotherapy followed by consolidation immunotherapy is standard of care (SOC) for unresectable locally advanced non-small cell lung cancer. This retrospective study enrolled 168 patients to compare survival and safety outcomes of the addition of induction therapy compared with the cCRT+ICI alone, with stabilized inverse probability weighting used to balance baseline patient characteristics. After adjustment, induction chemotherapy only prolonged progression-free survival (PFS) in patients with tumor response to induction, whereas induction chemoimmunotherapy significantly improved PFS relative to both standard treatment and induction chemotherapy, without increasing severe toxic events. No overall survival differences existed across groups. This real-world evidence clarifies the distinct clinical value of different induction strategies and guides personalized treatment selection for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.